Who was sanctioned, and for what?

From 2018 to 2021, the pharmaceutical manufacturer allegedly used two patient assistance foundations to fund Medicare beneficiaries’ co-payments for its drug Oxervate in order to promote its sales. Following a self-disclosure, Dompé paid 32 million USD.

Authority / court

U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Mitigating circumstances

Self-disclosure.

Original amount 32,000,000 USD, converted at the ECB reference rate of 10 Sep 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Between February 2018 and September 2019, five leaks of highly flammable hydrocarbons occurred at the Mossmorran major hazard site (COMAH upper tier), all caused by corrosion under insulation; around 82 tonnes escaped in one leak. During a routine inspection in May 2019, inspectors of the Health and Safety Executive (HSE) smelled escaping gas – the company had known about this leak for around four months and had continued production without additional precautions. The inspection arrangements for insulated pipework were inadequate; fine of 267,000 GBP.

Authority / court

Health and Safety Executive (Kirkcaldy Sheriff Court)

Area of law

Health and safety and employment law · Workplace safety and accidents

Legal basis

Provision and Use of Work Equipment Regulations 1998, reg. 6(2); Health and Safety at Work etc. Act 1974, s. 33(1)(c)

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

26 Aug 2026

Original amount 267,000 GBP, converted at the ECB reference rate of 25 Aug 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Henkel wanted to buy the construction adhesive brand Liquid Nails for 725 million USD from the financial investor American Industrial Partners, thereby taking over the main competitor of its Loctite brand. After a seven-day trial, the federal court, on application by the Federal Trade Commission (FTC), issued a permanent injunction against the acquisition.

Authority / court

U.S. District Court for the Southern District of New York (auf Antrag der FTC)

Area of law

Competition law · Merger control

Legal basis

Section 7 Clayton Act; Section 13(b) FTC Act (Permanent Injunction)

Action

Order

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

17 Aug 2026

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

From 2016 to 2023, Veloxis provided transplant professionals with expensive meals and alcohol, trips and stays at luxury resorts, gifts and consultancy fees without consideration, and paid specialty pharmacies concealed remuneration in order to promote prescriptions and purchases of the immunosuppressant Envarsus XR. The company entered into a Deferred Prosecution Agreement with a criminal payment of more than 10 million USD, is paying 34.45 million USD under civil law (21,211,251 USD to the federal government, 13,238,749 USD to states) and a penalty of 1.55 million USD under the Sunshine Act (Open Payments) – the highest to date – totalling over 46 million USD.

Authority / court

U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute; False Claims Act; Physician Payments Sunshine Act (Open Payments)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

The U.S. Forced Labor Enforcement Task Force (FLETF) listed the manufacturer of cephalosporin antibiotics because it sources antibiotic intermediates from Yili Chuanning Biotechnology in Xinjiang. The company's goods are therefore presumed to have been produced with forced labour on import into the US unless the importer rebuts this.

Authority / court

U.S. Department of Homeland Security (Forced Labor Enforcement Task Force)

Area of law

Supply chain and human rights · Forced and child labour

Legal basis

Uyghur Forced Labor Prevention Act, Section 2(d)(2)(B)(v)

Action

Order

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Published

3 Aug 2026

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Between January 2019 and March 2023, the pharmaceutical manufacturer allegedly paid kickbacks to ambulatory surgery centres to induce them to purchase and use the injectable drug DEXYCU for cataract surgery. To resolve the False Claims Act allegations, EyePoint paid 4,657,463.18 USD and entered into a Corporate Integrity Agreement with HHS-OIG.

Authority / court

U.S. Department of Justice

Area of law

Bribery and corruption · Commercial bribery

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Original amount 4,657,463.18 USD, converted at the ECB reference rate of 20 Jul 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.

Authority / court

U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Following its 2020 guilty plea, the opioid manufacturer was sentenced in Newark to a criminal fine of 3.544 billion USD (asserted in the insolvency proceedings) and forfeiture of 2 billion USD; up to 1.775 billion USD can be credited against the forfeiture if Purdue emerges from insolvency as a public benefit company. Purdue had deceived the DEA and paid kickbacks to prescribers via its speaker programme and to an electronic health records platform in order to increase opioid prescriptions.

Authority / court

U.S. District Court, District of New Jersey (Anklage: U.S. Department of Justice)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Verschwörung zum Betrug der USA und zur Verletzung des Food, Drug, and Cosmetic Act; zwei Fälle Verschwörung zur Verletzung des Anti-Kickback Statute (Schuldbekenntnis vom 24.11.2020)

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Culpability

intentional

Original amount 5,544,000,000 USD, converted at the ECB reference rate of 28 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In 2019, an employee stepped into a puddle of caustic soda; his safety boots offered no protection, and his leg had to be amputated below the knee. In 2022, another worker suffered chemical burns during manual decanting. The Health and Safety Executive (HSE) found leaking pipes and valves, a lack of maintenance, no risk assessment for decanting and untested safety footwear; fine of 3.8 million GBP plus 124,748 GBP in costs.

Authority / court

Health and Safety Executive (Southwark Crown Court)

Area of law

Health and safety and employment law · Workplace safety and accidents

Legal basis

Control of Substances Hazardous to Health Regulations 2002, reg. 7(1)

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Published

24 Apr 2026

Original amount 3,800,000 GBP, converted at the ECB reference rate of 21 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

While flange bolts were being removed from a steam trap in November 2023, a corroded isolation valve failed and high-pressure steam escaped; the contractor's fitter narrowly escaped serious injury. The agrochemicals group had not maintained work equipment and had not assessed the risk despite known corrosion (only single instead of double isolation). The Health and Safety Executive (HSE) prosecution resulted in a fine of 400,000 GBP plus 8,288 GBP in costs.

Authority / court

Health and Safety Executive (Leeds Magistrates' Court)

Area of law

Health and safety and employment law · Workplace safety and accidents

Legal basis

Provision and Use of Work Equipment Regulations 1998, reg. 5(1); Management of Health and Safety at Work Regulations 1999, reg. 3(1)

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

28 Jan 2026

Original amount 400,000 GBP, converted at the ECB reference rate of 28 Jan 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

A routine inspection in 2023 found that the company was selling eyeliners containing the PFAS substance perfluorononyl dimethicone without submitting the required notification of a ‘significant new activity’; a subsequent compliance order was not complied with. The court imposed 750,000 CAD; the company must inform its shareholders and is listed in the Environmental Offenders Registry.

Authority / court

Ontario Court of Justice (Ermittlungen: Environment and Climate Change Canada)

Area of law

Environment and sustainability · Waste and hazardous substances

Legal basis

Canadian Environmental Protection Act, 1999 (Significant New Activity, Compliance Order)

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Published

2 Feb 2026

Original amount 750,000 CAD, converted at the ECB reference rate of 13 Jan 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In 2019, as a result of an equipment defect, sodium chlorite entered the Rivière du Lièvre twelve times from the ERCO Mondial chemical plant in Gatineau; in the last incident, the authorities were only informed after five days. The company was fined 1.35 million CAD, and the then technical and environmental director 15,000 CAD.

Authority / court

Court of Québec (Ermittlungen: Environment and Climate Change Canada)

Area of law

Environment and sustainability · Waste and hazardous substances

Legal basis

Fisheries Act (Einbringen schädlicher Stoffe; unterlassene sofortige Meldung)

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Liability of senior managers

Jean-François Roux, the plant's then technical and environmental director, was personally fined 15,000 CAD.

Published

8 Jan 2026

Original amount 1,365,000 CAD, converted at the ECB reference rate of 7 Jan 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Following a loss of steam in April 2019, the ethylene plant in Fife flared for almost a week; the smoke significantly exceeded permit limits, and the Scottish Environment Protection Agency (SEPA) received over 900 complaints. Existing procedures and emergency plans should have prevented the incident but were not adequately followed. The company pleaded guilty and was fined 176,000 GBP.

Authority / court

Kirkcaldy Sheriff Court (Ermittlungen: Scottish Environment Protection Agency, SEPA)

Area of law

Environment and sustainability · Emissions and permits

Legal basis

Regulation 67(1)(b) Pollution Prevention and Control (Scotland) Regulations 2012; Section 2 Pollution Prevention and Control Act 1999

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Culpability

negligent

Published

28 Oct 2025

Original amount 176,000 GBP, converted at the ECB reference rate of 28 Oct 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In 2022, the Moscow office of the British subsidiary made payments – mainly salaries – to accounts at Alfa-Bank, Promsvyazbank, Sberbank and VTB; after deduction of payments covered by a general licence, around 128,300 GBP remained in breach. The approval process in the UK checked only the amount and the recipient, not the bank; because of a four-month delay in reporting, HM Treasury's Office of Financial Sanctions Implementation (OFSI) granted only a 35% instead of a 50% reduction.

Authority / court

HM Treasury, Office of Financial Sanctions Implementation (OFSI)

Area of law

Sanctions and export control · Breaches of sanctions and embargoes

Legal basis

Russia (Sanctions) (EU Exit) Regulations 2019, reg. 12

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Mitigating circumstances

Disclosure and full cooperation, but delayed

Published

30 Sep 2025

Original amount 152,750 GBP, converted at the ECB reference rate of 10 Sep 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In consignment agreements, the pharmaceutical wholesaler had made payment to suppliers of food supplements dependent on subsequent resale (payment period over 30 days) and had reserved the right to hold suppliers liable for spoiled goods. The Konkurentsiamet (Estonian Competition Authority) found infringements of the act on unfair trading practices in the food supply chain and ordered amended contractual terms.

Authority / court

Konkurentsiamet (Estnische Wettbewerbsbehörde)

Area of law

Competition law · Abuse of market power

Legal basis

§ 4 Abs. 1 und 2, § 5 Abs. 2, § 7 Abs. 1 PTEKS (UTP-Richtlinie (EU) 2019/633)

Action

Order

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In 2016–2021, the Texas supplier of catalysts for refineries and steelworks supplied products and advice to customers in Iran via its former CEO, employees and agents, and sold goods to a blocked Venezuelan company. The US Treasury's Office of Foreign Assets Control (OFAC) considered it an egregious but voluntarily self-disclosed case; there were parallel settlements with the DOJ and BIS, which were taken into account in determining the amount.

Authority / court

U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)

Area of law

Sanctions and export control · Breaches of sanctions and embargoes

Legal basis

Iranian Transactions and Sanctions Regulations; Venezuela Sanctions Regulations; IEEPA

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Culpability

intentional

Mitigating circumstances

Voluntary self-disclosure, cooperation and remedial measures after discovery

Liability of senior managers

According to OFAC, the violations were carried out by the former CEO and co-founder as well as former employees.

Published

16 Jun 2025

Original amount 3,882,797 USD, converted at the ECB reference rate of 16 Jun 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.

Authority / court

U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

29 Apr 2025

Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Over more than 15 years, the three OTC medicine manufacturers jointly developed the category management project ‘SMAN’, through which they steered the placement of non-prescription medicines in selected pharmacies in their favour and disadvantaged or excluded competing products. In a settlement procedure, the Autorité belge de la Concurrence / Belgische Mededingingsautoriteit (Belgian Competition Authority, BMA) imposed a total of 11,249,280.48 EUR.

Authority / court

Autorité belge de la Concurrence / Belgische Mededingingsautoriteit (BMA)

Area of law

Competition law · Cartels and collusion

Legal basis

Code de droit économique Art. IV.1; AEUV Art. 101

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

24 Apr 2025

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

The biotech company did not disclose as soon as possible the FDA's request for an additional study on PXT-3003 and the subsequent rejection of an SPA application, and disseminated misleading communications to shareholders. Sanctions: Pharnext 500,000 EUR, former CEO Daniel Cohen 200,000 EUR, former CEO David Horn Solomon 100,000 EUR.

Authority / court

Autorité des marchés financiers (AMF), Commission des sanctions

Area of law

Capital markets and financial supervision · Disclosure and reporting obligations

Legal basis

Art. 17 MAR; Art. 12 Abs. 1 lit. c und Art. 15 MAR

Action

Fine

Status of proceedings

under appeal

Sector

Chemicals and pharmaceuticals

Liability of senior managers

Daniel Cohen (co-founder, directeur général until April 2020): 200,000 EUR; David Horn Solomon (directeur général from April 2020): 100,000 EUR

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In July 2024, nitrogen dioxide above the exposure limit was released during chemical processing at the plant of Zep subsidiary AFCO in Chambersburg (Pennsylvania); twelve employees were examined in hospital and two were admitted. The U.S. Occupational Safety and Health Administration (OSHA) criticised the lack of an emergency action plan, deficient respiratory protection and hazard communication programmes and a delayed evacuation, and proposed $161,310 (including one repeat violation).

Authority / court

U.S. Department of Labor – Occupational Safety and Health Administration (OSHA)

Area of law

Health and safety and employment law · Workplace safety and accidents

Legal basis

29 CFR 1910.120, 1910.134, 1910.1200

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Repeat case

yes

Published

14 Jan 2025

Original amount 161,310 USD, converted at the ECB reference rate of 14 Jan 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

During the review of the sale of the European rights to the hormone products Duphaston and Femoston to Theramex, an Initial Enforcement Order was in force. Viatris replaced members of the UK management without the consent of the Competition and Markets Authority (CMA) and subsequently failed to report the breach; the CMA imposed 1.5 million GBP.

Authority / court

Competition and Markets Authority (CMA)

Area of law

Competition law · Merger control

Legal basis

Enterprise Act 2002, s. 72(2) (Initial Enforcement Order), s. 94A

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Original amount 1,500,000 GBP, converted at the ECB reference rate of 22 Nov 2024.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

Teva abused its dominant position for the MS medicine Copaxone: it artificially extended patent protection by filing staggered divisional applications with the EPO and strategically withdrawing them, and spread misleading statements about an authorised competing product among physicians and decision-makers. Seven Member States were affected over periods of four to nine years.

Authority / court

Europäische Kommission

Area of law

Competition law · Abuse of market power

Legal basis

Art. 102 AEUV

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

In 2017–2018, the Thai plastics company had US banks process 467 payments totalling 291 million USD for HDPE plastic produced in an Iranian joint venture with the state-owned National Petrochemical Company. Shipping and documentation practices concealed the Iranian origin. The penalty was imposed by the US Treasury's Office of Foreign Assets Control (OFAC).

Authority / court

U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)

Area of law

Sanctions and export control · Breaches of sanctions and embargoes

Legal basis

Iranian Transactions and Sanctions Regulations (31 C.F.R. part 560)

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Culpability

intentional

Published

19 Apr 2024

Original amount 20,000,000 USD, converted at the ECB reference rate of 19 Apr 2024.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report

From 2005 to 2019, six manufacturers and traders of the active ingredient SNBB (the base substance for Buscopan and generics) fixed minimum prices, allocated quotas and exchanged sensitive information. This was the first cartel concerning an active pharmaceutical ingredient that the Commission has sanctioned; C2 PHARMA received full immunity, and all parties reached a settlement.

Authority / court

Europäische Kommission

Area of law

Competition law · Cartels and collusion

Legal basis

Art. 101 AEUV, Art. 53 EWR-Abkommen

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Mitigating circumstances

Leniency programme (C2 PHARMA 100 %, Transo-Pharm 50 %, Linnea 30 %), 10 % settlement reduction

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Website What is wrong? Please include evidence if possible.

Anonymous: we store only your text — no contact details and no IP address.

Send report